The estimated Net Worth of Sophie V. Vandebroek is at least $1.01 Milión dollars as of 6 May 2024. Sophie Vandebroek owns over 257 units of Idexx Laboratories stock worth over $722,153 and over the last 11 years he sold IDXX stock worth over $0. In addition, he makes $287,482 as Independent Director at Idexx Laboratories.
Sophie has made over 11 trades of the Idexx Laboratories stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 257 units of IDXX stock worth $125,997 on 6 May 2024.
The largest trade he's ever made was exercising 9,044 units of Idexx Laboratories stock on 5 August 2019 worth over $580,534. On average, Sophie trades about 1,065 units every 123 days since 2013. As of 6 May 2024 he still owns at least 1,473 units of Idexx Laboratories stock.
You can see the complete history of Sophie Vandebroek stock trades at the bottom of the page.
Dr. Sophie V. Vandebroek Ph.D. serves as Independent Director of the Company. Previously, Dr. Vandebroek served as Vice President, Emerging Technology Partnerships for International Business Machines, Inc. (IBM) from August 2018 to August 2019 and Chief Operating Officer - IBM Research from January 2017 to August 2018. Prior to joining IBM, she was an executive with Xerox Corporation where she served as Chief Technology Officer and Corporate Vice President of Xerox Corporation and President of the Xerox Innovation Group from January 2006 to December 2016 and was Chief Engineer of Xerox Corporation from 2002 to 2005. Dr. Vandebroek was also responsible for overseeing Xerox’s global research centers, including the Palo Alto Research Center, or PARC Inc. Dr. Vandebroek has been a member of the Advisory Council of the Dean of the School of Engineering at Massachusetts Institute of Technology since 2010. She is a Fellow of the Institute of Electrical & Electronics Engineers, a Fulbright Fellow and a Fellow of the Belgian-American Educational Foundation. Dr. Vandebroek holds an undergraduate degree in engineering and a master’s degree in electro-mechanical engineering from KU Leuven, Leuven, Belgium, and a PhD in electrical engineering from Cornell University.
As the Independent Director of Idexx Laboratories, the total compensation of Sophie Vandebroek at Idexx Laboratories is $287,482. There are 18 executives at Idexx Laboratories getting paid more, with Jonathan Ayers having the highest compensation of $8,309,800.
Sophie Vandebroek is 58, he's been the Independent Director of Idexx Laboratories since 2013. There are 10 older and 13 younger executives at Idexx Laboratories. The oldest executive at Idexx Laboratories, Inc. is M. Anne Szostak, 69, who is the Independent Director.
Sophie's mailing address filed with the SEC is ONE IDEXX DRIVE, , WESTBROOK, ME, 04092.
Over the last 22 years, insiders at Idexx Laboratories have traded over $238,711,289 worth of Idexx Laboratories stock and bought 24,695 units worth $3,109,424 . The most active insiders traders include Stuart Essig, Johnny D Powers a Jonathan W Ayers. On average, Idexx Laboratories executives and independent directors trade stock every 9 days with the average trade being worth of $4,641,291. The most recent stock trade was executed by M Anne Szostak on 5 September 2024, trading 500 units of IDXX stock currently worth $234,685.
idexx laboratories, inc. (nasdaq: idxx) is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. headquartered in southern maine, idexx conducts operations through more than 70 locations around the world, serves customers in over 175 countries, and employs more than 6,000 people. idexx's primary business focuses on pet health, a growing market around the world. idexx products —in-clinic diagnostic tests and instrumentation, reference laboratory and telemedicine consultation services, and practice management software—enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. idexx also develops and manufactures diagnostic tests and information for the global production animal industry, including poultry and livestock, as well as tests for the quality and safety of water an
Idexx Laboratories executives and other stock owners filed with the SEC include: